Previous 10 | Next 10 |
Organigram Holdings Inc. (OGI) is expected to report $-0.06 for Q2 2024 COMSovereign Holding Corp. (COMS) is expected to report for quarter end 2023-12-31 PriceSmart Inc. (PSMT) is expected to report for Q2 2024 Tilray Brands Inc. (TLRY) is expected to report $-0.04 for Q3 2024 Ux...
Connect Biopharma Holdings Limited (CNTB) is expected to report for Q4 2023
2024-04-01 12:57:59 ET More on Mid-day movers & stocks. Meta Materials total Q4 revenue up 55% y/y Meta Materials announces $1M civil penalty to settle SEC investigation Seeking Alpha’s Quant Rating on Connect Biopharma Historical earnings data for...
SAN DIEGO and TAICANG, China, March 19, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflam...
James Huang brings over 30 years of biotech experience as a successful entrepreneur, investor and key opinion leader in the healthcare sector SAN DIEGO, CA and TAICANG, China, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma...
2023-12-29 08:37:32 ET China SXT Pharmaceuticals ( SXTC ) +161% . China Green Agriculture ( CGA ) +71% . Sentage Holdings ( SNTG ) +24% . Tantech Holdings ( TANH ) +20% . FLJ Group FLJ +20% reported the completion of acquisition of Alp...
2023-12-17 02:00:00 ET Summary SystImmune out-licenses global rights for a bispecific ADC to Bristol Myers Squibb in an $8.4 billion agreement. Evive Biotech forms an antibody discovery collaboration with Nona Biosciences to accelerate the process of antibody discovery and drug de...
2023-12-12 06:49:53 ET More on Connect Biopharma Connect Biopharma stock rises on positive data from dermatitis mAb Seeking Alpha’s Quant Rating on Connect Biopharma Historical earnings data for Connect Biopharma Financial information for Connect Bioph...
The global trial met its primary endpoint showing both doses of rademikibart treatment significantly improved lung function at Week 12 The significant improvement in lung function was observed as early as Week 1 and was sustained through Week 24 with both doses of rademikibart Significant...
SAN DIEGO, CA and TAICANG, China, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inf...
News, Short Squeeze, Breakout and More Instantly...
Connect Biopharma Holdings Limited Company Name:
CNTB Stock Symbol:
NASDAQ Market:
Connect Biopharma Holdings Limited Website:
SAN DIEGO, CA and TIACANG, China, July 01, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases thr...
SAN DIEGO, CA and TAICANG, China, June 12, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases thr...
Rademikibart treatment significantly improved lung function at Week 12; improvements were observed as early as Week 1 and sustained through Week 24 Significant improvement in patient-reported asthma control occurred early and was sustained through Week 24 End of Phase 2 (EoP2) meeting i...